Indication

PIK3CA Mutation-Related Tumors

1 clinical trial

1 product

Clinical trial

A Phase Ib/IIa Study to Evaluate the Safety and Preliminary Efficacy of WX390, a PI3K/mTOR Dual Inhibitor, for the Treatment of Advanced Solid Tumors With PIK3CA Mutations

Status: Completed, Estimated PCD: 2023-01-03

Product